{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:40:45Z","timestamp":1768621245604,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1124\/jpet.121.001004","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T13:35:11Z","timestamp":1645968911000},"page":"151-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetic\/Pharmacodynamic Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis"],"prefix":"10.1016","volume":"381","author":[{"given":"Artur","family":"\u015awierczek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Pomierny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Wyska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Jusko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.001004_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.121.001004_bib2","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1093\/ofid\/ofz360.801","article-title":"733. Pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) analyses for alanine aminotransferase (ALT) using phase 3 data from omadacycline (OMC)-treated patients","volume":"6","author":"Bhavnani","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1124\/jpet.121.001004_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4049\/jimmunol.164.2.1117","article-title":"Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases","volume":"164","author":"Bielekova","year":"2000","journal-title":"J Immunol"},{"key":"10.1124\/jpet.121.001004_bib4","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.bbamem.2011.04.013","article-title":"Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels","volume":"1808","author":"Bobak","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.121.001004_bib5","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2006.02.045","article-title":"Are phosphodiesterase 4 inhibitors just more theophylline?","volume":"117","author":"Boswell-Smith","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1124\/jpet.121.001004_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1440-1711.1998.00779.x","article-title":"IL-6, IFN-gamma and TNF-alpha production by liver-associated T cells and acute liver injury in rats administered concanavalin A","volume":"76","author":"Cao","year":"1998","journal-title":"Immunol Cell Biol"},{"key":"10.1124\/jpet.121.001004_bib7","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fimmu.2018.01662","article-title":"Apremilast ameliorates experimental arthritis via suppression of Th1 and Th17 cells and enhancement of CD4+Foxp3+ regulatory T cells differentiation","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.121.001004_bib8","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.121.001004_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejmech.2018.01.068","article-title":"Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4\/7 inhibitors with potential anti-inflammatory activity: design, synthesis and biological evaluation","volume":"146","author":"Ch\u0142o\u0144-Rzepa","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1124\/jpet.121.001004_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2478\/v10201-011-0023-7","article-title":"Selective inhibition of phosphodiesterase 7 (PDE7) by BRL50481 in healthy and ovalbumin-sensitized guinea pigs","volume":"12","author":"Christensen","year":"2012","journal-title":"Acta Medica Martiniana"},{"key":"10.1124\/jpet.121.001004_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3350\/cmh.2016.0089","article-title":"The use of immunosuppression in autoimmune hepatitis: a current literature review","volume":"23","author":"Cropley","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1124\/jpet.121.001004_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5009\/gnl15352","article-title":"Diagnosis and management of autoimmune hepatitis: current status and future directions","volume":"10","author":"Czaja","year":"2016","journal-title":"Gut Liver"},{"key":"10.1124\/jpet.121.001004_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/apt.12825","article-title":"Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets","volume":"40","author":"Czaja","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.121.001004_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.121.001004_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jlb.63.1.101","article-title":"Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production","volume":"63","author":"Eigler","year":"1998","journal-title":"J Leukoc Biol"},{"key":"10.1124\/jpet.121.001004_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00280-007-0583-8","article-title":"Semimechanistic pharmacokinetic\/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment","volume":"62","author":"Fetterly","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.121.001004_bib17","doi-asserted-by":"crossref","first-page":"e2462","DOI":"10.1038\/cddis.2016.362","article-title":"RIPK1 protects from TNF-\u03b1-mediated liver damage during hepatitis","volume":"7","author":"Filliol","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1124\/jpet.121.001004_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-3565(24)36389-X","article-title":"Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors","volume":"280","author":"Gantner","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.121.001004_bib19","first-page":"190","article-title":"Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor","volume":"21","author":"Gantner","year":"1995","journal-title":"Hepatology"},{"key":"10.1124\/jpet.121.001004_bib20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/j.1476-5381.1996.tb15629.x","article-title":"Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2","volume":"118","author":"Giembycz","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.121.001004_bib21","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.intimp.2009.08.002","article-title":"Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice","volume":"9","author":"Goto","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1124\/jpet.121.001004_bib60","doi-asserted-by":"crossref","first-page":"16152","DOI":"10.1074\/jbc.272.26.16152","article-title":"Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart","volume":"272","author":"Han","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.121.001004_bib61","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/bj3280549","article-title":"Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3","volume":"328","author":"Huston","year":"1997","journal-title":"Biochem J"},{"key":"10.1124\/jpet.121.001004_bib22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2174\/0929867324666170116125159","article-title":"PDE7-selective and dual inhibitors: advances in chemical and biological research","volume":"24","author":"Jankowska","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.121.001004_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.103.061515","article-title":"Receptor\/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver","volume":"309","author":"Jin","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.121.001004_bib24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/mol.117.110825","article-title":"CAMP signaling compartmentation: adenylyl cyclases as anchors of dynamic signaling complexes","volume":"93","author":"Johnstone","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.121.001004_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1872-034X.2011.00773.x","article-title":"Cytokine profiles affecting the pathogenesis of autoimmune hepatitis in Japanese patients","volume":"41","author":"Kamijo","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1124\/jpet.121.001004_bib26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaci.2004.10.019","article-title":"IL-17 cytokine family","volume":"114","author":"Kawaguchi","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1124\/jpet.121.001004_bib27","doi-asserted-by":"crossref","first-page":"14090","DOI":"10.1038\/s41598-017-13021-y","article-title":"Activation of PKA in cell requires higher concentration of cAMP than in vitro: implications for compartmentalization of cAMP signalling","volume":"7","author":"Koschinski","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.121.001004_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/00498258809041693","article-title":"Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences","volume":"18","author":"Krause","year":"1988","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.121.001004_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1741-7015-11-96","article-title":"Phosphodiesterase 4-targeted treatments for autoimmune diseases","volume":"11","author":"Kumar","year":"2013","journal-title":"BMC Med"},{"key":"10.1124\/jpet.121.001004_bib30","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4049\/jimmunol.154.3.1307","article-title":"Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release","volume":"154","author":"Leist","year":"1995","journal-title":"J Immunol"},{"key":"10.1124\/jpet.121.001004_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10928-020-09720-1","article-title":"A general model for cell death and biomarker release from injured tissues","volume":"48","author":"Li","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/jpet.121.001004_bib32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","article-title":"Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake","volume":"19","author":"Liu","year":"2001","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1124\/jpet.121.001004_bib33","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.3748\/wjg.14.3292","article-title":"Historical reflections on autoimmune hepatitis","volume":"14","author":"Mackay","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1124\/jpet.121.001004_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jchemneu.2016.12.001","article-title":"A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice","volume":"80","author":"Mart\u00edn-\u00c1lvarez","year":"2017","journal-title":"J Chem Neuroanat"},{"key":"10.1124\/jpet.121.001004_bib35","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/molecules23092287","article-title":"Pharmacokinetic and pharmacodynamic properties of rosmarinic acid in rat cholestatic liver injury","volume":"23","author":"Min","year":"2018","journal-title":"Molecules"},{"key":"10.1124\/jpet.121.001004_bib36","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.4049\/jimmunol.181.11.7473","article-title":"Requirement of IL-17RA in Con A induced hepatitis and negative regulation of IL-17 production in mouse T cells","volume":"181","author":"Nagata","year":"2008","journal-title":"J Immunol"},{"key":"10.1124\/jpet.121.001004_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1254\/jjp.77.147","article-title":"Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains","volume":"77","author":"Ohsawa","year":"1998","journal-title":"Jpn J Pharmacol"},{"key":"10.1124\/jpet.121.001004_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fimmu.2016.00123","article-title":"The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases","volume":"7","author":"Raker","year":"2016","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.121.001004_bib39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.25656","article-title":"Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: early discrimination between survival and death","volume":"56","author":"Remien","year":"2012","journal-title":"Hepatology"},{"key":"10.1124\/jpet.121.001004_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112854","article-title":"New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases","volume":"209","author":"Ru\u010dilov\u00e1","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1124\/jpet.121.001004_bib41","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1006\/cyto.1998.0375","article-title":"Regulation of IL-17, IFN-\u03b3 and IL-10 in human CD8(+) T cells by cyclic AMP-dependent signal transduction pathway","volume":"10","author":"Shin","year":"1998","journal-title":"Cytokine"},{"key":"10.1124\/jpet.121.001004_bib42","article-title":"Contrasting model mechanisms of alanine aminotransferase (ALT) release from damaged and necrotic hepatocytes as an example of general biomarker mechanisms","volume":"16","author":"Smith","year":"2019","journal-title":"bioRxiv"},{"key":"10.1124\/jpet.121.001004_bib41a","doi-asserted-by":"crossref","first-page":"L279","DOI":"10.1152\/ajplung.00170.2002","article-title":"Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells","volume":"284","author":"Smith","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1124\/jpet.121.001004_bib43","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/mol.104.002246","article-title":"Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes","volume":"66","author":"Smith","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.121.001004_bib44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/pharmaceutics13050597","article-title":"PK\/PD modeling of the PDE7 inhibitor\u2014GRMS-55 in a mouse model of autoimmune hepatitis","volume":"13","author":"\u015awierczek","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1124\/jpet.121.001004_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11095-019-2727-z","article-title":"Comparative assessment of the new PDE7 inhibitor \u2013 GRMS-55 and lisofylline in animal models of immune-related disorders: a PK\/PD modeling approach","volume":"37","author":"\u015awierczek","year":"2020","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.121.001004_bib46","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00210-017-1406-z","article-title":"PK\/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response","volume":"390","author":"\u015awierczek","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.121.001004_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1386-6346(03)00263-8","article-title":"Gender-related differences in concanavalin A-induced liver injury and cytokine production in mice","volume":"27","author":"Takamoto","year":"2003","journal-title":"Hepatol Res"},{"key":"10.1124\/jpet.121.001004_bib48","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Terziroli Beretta-Piccoli","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1124\/jpet.121.001004_bib49","article-title":"Autoimmune hepatitis: progress from global immunosuppression to personalised regulatory T cell therapy","volume":"2016","author":"Than","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1124\/jpet.121.001004_bib50","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0016-5085(98)70324-5","article-title":"Concanavalin A-induced liver cell damage: activation of intracellular pathways triggered by tumor necrosis factor in mice","volume":"114","author":"Trautwein","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.121.001004_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3748\/wjg.v18.i2.119","article-title":"Immune mechanisms of Concanavalin A model of autoimmune hepatitis","volume":"18","author":"Wang","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1124\/jpet.121.001004_bib52","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fimmu.2016.00222","article-title":"Molecular mechanisms for cAMP-mediated immunoregulation in T cells - role of anchored protein kinase a signaling units","volume":"7","author":"Wehbi","year":"2016","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.121.001004_bib53","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4049\/jimmunol.166.2.1300","article-title":"TNF-\u03b1-induced expression of adhesion molecules in the liver is under the control of TNFR1--relevance for concanavalin A-induced hepatitis","volume":"166","author":"Wolf","year":"2001","journal-title":"J Immunol"},{"key":"10.1124\/jpet.121.001004_bib54","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/eji.201141291","article-title":"Regulation of the development of acute hepatitis by IL-23 through IL-22 and IL-17 production","volume":"41","author":"Xu","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1124\/jpet.121.001004_bib55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/icb.2011.59","article-title":"Critical role of interleukin-17\/interleukin-17 receptor axis in mediating Con A-induced hepatitis","volume":"90","author":"Yan","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1124\/jpet.121.001004_bib56","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.4049\/jimmunol.171.12.6414","article-title":"Phosphodiesterase 7A-deficient mice have functional T cells","volume":"171","author":"Yang","year":"2003","journal-title":"J Immunol"},{"key":"10.1124\/jpet.121.001004_bib57","series-title":"A Comprehensive Guide to Toxicology in Nonclinical Drug Development","first-page":"325","article-title":"Clinical Pathology","author":"York","year":"2017"},{"key":"10.1124\/jpet.121.001004_bib58","first-page":"454","article-title":"An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats","volume":"15","author":"Yoshioka","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1124\/jpet.121.001004_bib59","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1124\/mol.62.3.514","article-title":"Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis","volume":"62","author":"Zhang","year":"2002","journal-title":"Mol Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.001004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:26:14Z","timestamp":1739971574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524002702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0022356524002702"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.001004","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic\/Pharmacodynamic Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.001004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}